Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert M Plenge is Director at Bristol Myers Squibb. OQRO lists 15 transactions filed with the SEC under this name, the latest on Sep 14, 2026, each linked to the official Form 4.
Director
Disclosures on record
15
Companies involved
2
Sep 10, 20266,140disclosed Sep 14
DetailsOfficial recordBristol Myers SquibbBMY
14 disclosures · Mar 2026
Mar 10, 202627Kdisclosed Mar 12
DetailsOfficial recordMar 10, 202618Kdisclosed Mar 12
DetailsOfficial recordMar 10, 20262,342disclosed Mar 12
DetailsOfficial recordMar 10, 20261,107disclosed Mar 12
DetailsOfficial recordMar 10, 202614Kdisclosed Mar 12
DetailsOfficial recordMar 10, 20261,107disclosed Mar 12
DetailsOfficial recordMar 10, 202614Kdisclosed Mar 12
DetailsOfficial recordMar 10, 20262,342disclosed Mar 12
DetailsOfficial recordMar 10, 2026124disclosed Mar 12
DetailsOfficial recordMar 10, 20266,900disclosed Mar 12
DetailsOfficial recordMar 10, 2026253disclosed Mar 12
DetailsOfficial recordMar 10, 20263,172disclosed Mar 12
DetailsOfficial recordMar 10, 2026927disclosed Mar 12
DetailsOfficial recordMar 10, 2026436disclosed Mar 12
DetailsOfficial recordAs of the latest filing on , Robert M Plenge reported holding 21,528 shares of Bristol Myers Squibb (BMY), worth about $1.27M at the last close of $59 (Nov 20, 2026). Holdings are also on file at BioMarin Pharmaceutical (BMRN); together they are worth about $1.64M.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Bristol Myers Squibb BMY | 21,528 | 22K direct | $59 | $1.27M | Mar 10, 2026 |
| BioMarin Pharmaceutical BMRN | 6,140 | 6,140 direct | $60 | $371K | Sep 10, 2026 |
Is this Robert M Plenge’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Robert M Plenge has no open-market purchase on record since 2023. Sales in 1 of the 4 years since 2023.
Robert M Plenge reported 0 open-market purchases and 1 sale since 2023; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2023 | — | $45K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Mar 10, 2026, Robert M Plenge reported holding 21,528 shares of Bristol Myers Squibb (BMY). At the last close of $59 on Nov 20, 2026, that is about $1.27M. This is the stake disclosed in filings, not a net worth.
No public filing gives Robert M Plenge's net worth. What SEC Form 4 shows is the stock stake: 21,528 shares of Bristol Myers Squibb (BMY), about $1.27M at the last close, plus holdings in 1 other company, about $1.64M in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Robert M Plenge has no open-market purchase on record since 2023. Sales in 1 of the 4 years since 2023.
In SEC filings since 2023: no open-market purchase is on record; the latest open-market sale is from 2023.
Bristol Myers Squibb (BMY), from 2023 to 2023: 0 purchases and 1 sale.
Robert M Plenge reported 0 open-market purchases and 1 sale here, 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.